疾病状态下II相代谢酶表达和活性的研究进展

doi:10.12092/j.issn.1009-2501.2020.06.012

摘要/Abstract

摘要： 通常认为II相代谢为解毒和灭活过程,在药物代谢和解毒过程中酶催化的结合反应起着十分重要的作用。在疾病状态下,药物II相代谢酶的表达和活性也会发生改变。疾病对人体药物代谢酶的影响可能具有同工酶选择性。研究疾病状态下II相代谢酶的变化,有助于了解II相代谢酶的调节机制,对于进一步研究以指导临床合理用药及疾病的预防治疗有重要作用。本文综述了II相代谢酶的分布及功能,阐述了它们在肝脏疾病、消化道疾病、糖尿病、癌症、神经退行性疾病、妇科疾病及心血管疾病下表达/活性的变化,探讨不同疾病下及疾病进展中各种II相代谢酶表达与活性的变化及差异的产生原因。

关键词: II相代谢酶, 疾病, 基因表达, 酶活性

Abstract: Phase II metabolism is generally considered to be a process of detoxification and inactivation. The enzymatic binding reaction plays a very important role in the process of drug metabolism and detoxification. Under disease status, the expression and activity of drug phase II metabolic enzymes will also change. The effects of disease on human drug metabolism enzymes may be isozyme selective. Studying the changes of phase II metabolic enzymes under disease status is helpful for understanding the regulation mechanism of phase II metabolic enzymes, and has an important role in further research to guide clinical rational drug usage and disease prevention and treatment. This article reviewed the distribution and function of phase II metabolic enzymes, and described their changes in expression/activity in liver disease, digestive tract disease, diabetes, cancer, neurodegenerative disease, glynecological disease and cardiovascular disease. The changes and causes of various phase II metabolizing enzymes under different disease and disease progression were also discussed.

Key words: phase II metabolic enzyme, disease, gene expression, enzyme activity

中图分类号:

R969.1

张钰, 彭英, 王广基, 孙建国. 疾病状态下II相代谢酶表达和活性的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(6): 686-700.

ZHANG Yu, PENG Ying, WANG Guangji, SUN Jianguo. Advances in study of phase II metabolic enzyme expression and activity under diseases status[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 686-700.

参考文献 84

[1]	Line S Braten, Tore Haslemo, Marin M, et al. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients[J]. Neuropsychopharmacology, 2020, 45(3): 570-576.
[2]	庄笑梅. 炎症诱发的药物代谢酶表型变化及其机制研究进展[J]. 国际药学研究杂志, 2015, 42(5): 541-547.
[3]	Liu F, Yu G, Wang G, et al. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer[J]. PLoS One, 2012, 7(7): e42138.
[4]	Luo YY, Nie Y, Tang L, et al. The correlation between UDP-glucuronosyltransferase polymorphisms and environmental endocrine disruptors levels in polycystic ovary syndrome patients [J]. Medicine, 2020, 99(99): e19444.
[5]	彭金咏, 栾连军. 尿苷二磷酸葡萄糖醛酸转移酶的研究进展 [J]. 中国现代应用药学, 2002, 19(5): 373-376.
[6]	Uno Y, Uehara S, Inoue T, et al. Molecular characterization of functional UDP-glucuronosyltransferases 1A and 2B in common marmosets [J]. Biochem Pharmacol, 2019, 172: 113748.
[7]	Nakamura A, Nakajima M, Yamanaka H, et al. Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines [J]. Drug Metab Dispos, 2008, 36(8): 1461-1464.
[8]	高欣, 吴疆, 袁永兵, 等. 尿苷二磷酸葡萄糖醛酸转移酶与内源性物质的相互作用 [J]. 药物评价研究, 2015, 38(4): 421-426.
[9]	Chen A, Zhou X, Cheng Y, et al. Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes [J].Toxicol Lett, 2018, 295: 379-389.
[10]	管睿. 硫酸基转移酶家族与妇科肿瘤 [J]. 国际妇产科学杂志, 2011, 38(4): 324-327.
[11]	王永辉, 奇锦峰, 张娜, 等. 硫酸基转移酶代谢功能相关的研究进展 [J]. 中国医院药学杂志, 2015, 35(2): 178-182.
[12]	Lindsay J, Wang LL, Li Y, et al. Structure, function and polymorphism of human cytosolic sulfotransferases [J]. Curr Drug Metab, 2008, 9(2): 99-105.
[13]	Marto N, Morello J, Monteiro EC, et al. Implications of Sulfotransferase Activity in Interindividual Variability in Drug Response: Clinical Perspective on Current Knowledge [J]. Drug Metab Rev, 2017, 49(3): 357-371.
[14]	常彬霞, 貌盼勇, 白冰珂, 等. 谷胱甘肽S转移酶的研究进展及其与肿瘤的相关性[J]. 解放军医学杂志, 2012, 49(8): 838-842.
[15]	Board PG, Menon D. Glutathione transferases, regulators of cellular metabolism and physiology [J]. Biochimica et Biophysica Acta, 2012, 1830(5): 3267-3288.
[16]	Board PG, Menon D. Structure, function and disease relevance of Omega-class glutathione transferases [J]. Arch Toxicol, 2016, 90(5): 1049-1067.
[17]	Mazzetti AP, Fiorile MC, Primavera A, et al. Glutathione transferases and neurodegenerative diseases[J]. Neurochemistry International, 2015, 82: 10-18.
[18]	Rigsby RE, Fillgrove KL, Beihoffer LA, et al. Fosfomycin Resistance Proteins: A Nexus of Glutathione Transferases and Epoxide Hydrolases in a Metalloenzyme Superfamily[J]. Methods Enzymol, 2005, 401: 367-379.
[19]	Blackburn AC, Tzeng HF, Anders MW, et al. Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysis [J]. Pharmacogenetics, 2000, 10(1): 49-57.
[20]	Siegel D, Dehn DD, Bokatzian SS, et al. Redox modulation of NQO1 [J]. Plos One, 2018, 13(1): e0190717.
[21]	夏小俊, 金中初. NQO1酶及其被氧环境诱导表达的研究进展 [J]. 生理科学进展, 2002, 33(3): 225-229.
[22]	Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues [J]. Free Radic Biol Med, 2000, 29(3/4): 246-253.
[23]	den Braver-Sewradj SP, den Braver MW, Toorneman RM, et al. Reduction and scavenging of chemically reactive drug metabolites by NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 and variability in hepatic concentrations [J]. Chem Res Toxicol, 2018, 31(2): 116-126.
[24]	den Braver-Sewradj SP, den Braver MW, van Dijk M, et al. Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals [J]. Curr Drug Metab, 2018, 19(4): 370-381.
[25]	Rougee LR, Riches Z, Berman JM, et al. The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1) [J]. Drug Metab Dispos, 2016, 44(7): 967-974.
[26]	Poon RWS, Tam EWT, Lau SKP, et al. Molecular identification of cestodes and nematodes by COX1 gene real-time PCR and sequencing [J]. Diagn Microbiol Infect Dis, 2017, 89(3): 185-190.
[27]	Lei BB, Ju F, Fu QR, et al. Mild hypothermia prevents noinduced cytotoxicity in human neuroblastoma cells via induction of COX-2 [J]. J Mol Neurosci, 2019, 67(2): 173-180.
[28]	Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system [J]. Br J Pharmacol, 2019, 176(8): 1038-1050.
[29]	杨诺, 李文. 血红素加氧酶1对肝脏缺血再灌注损伤的保护作用 [J]. 医学综述, 2019, 25(12): 2289-2293, 2298.
[30]	Loboda A, Damulewicz M, Pyza E, et al. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism [J]. Cell Mol Life Sci, 2016, 73(17): 3221-3247.
[31]	姜杉, 郝海平, 王广基. 肝损状态下尿苷二磷酸葡萄糖醛酸转移酶研究进展 [J]. 中国临床药理学与治疗学, 2009, 14(12): 7-14.
[32]	胡小玲. 大鼠肝纤维化状态下肝脏和小肠药物代谢功能的改变 [D]. 武汉大学, 2004.
[33]	Hardwick RN, Ferreira DW, More VR, et al. Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease [J]. Drug Metab Dispos, 2013, 41(3): 554-561.
[34]	Yalcin EB, More V, Neira KL, et al. Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers [J]. Drug Metab Dispos, 2013, 41(9): 1642-1650.
[35]	Dzierlenga AL, Clarke JD, Hargraves TL, et al. Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis [J]. J Pharmacol Exp Ther, 2015, 352(3): 462-470.
[36]	Abdalla MY, Britigan BE, Wen F, et al. Down-Regulation of Heme Oxygenase-1 by Hepatitis C Virus Infection In Vivo and by the In Vitro Expression of Hepatitis C Core Protein[J]. J Infect Dis, 2004, 190(6): 1109-1118.
[37]	中华医学会消化病学分会炎症性肠病学组. 建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见[J]. 中华炎性肠病杂志, 2017, 1(1): 12-19.
[38]	郑全理, 杨飞丹. 肠道菌群平衡在肠炎类疾病诊治中的意义 [J]. 中国卫生工程学, 2018, 17(4): 563-564.
[39]	梁志强, 郑彤, 高兴旺. 黄芩素在溃疡性结肠炎模型大鼠肝、肠微粒体中酶促反应动力学研究 [J]. 中南药学, 2016(12): 1302-1307.
[40]	Zhou X, Xie Y, Qi Q, et al. Disturbance of Hepatic and Intestinal UDP-glucuronosyltransferase in Rats with Trinitrobenzene Sulfonic Acid-induced Colitis[J]. Drug Metab Pharmacokinet, 2013, 28(4): 305-313.
[41]	刘波, 许春梅. HIF-1α、COX-2在溃疡性结肠炎中的表达及与疾病活动性的关系 [J]. 临床消化病杂志, 2008, 20(3): 172-175.
[42]	沈锡中. 环氧合酶-2对乙酸诱导大鼠胃溃疡形成和愈合的影响 [J]. 中华医学杂志, 2001, 81(22): 39-42.
[43]	Chen WY, Zhang J, Ghare S, et al. Acrolein Is a Pathogenic Mediator of Alcoholic Liver Disease and the Scavenger Hydralazine Is Protective in Mice [J]. Cell Mol Gastroenterol Hepatol, 2016, 2(5): 685-700.
[44]	Ronis MJ, Mercer KE, Gannon B, et al. Increased 4-hydroxynonenal protein adducts in male GSTA4-4/PPAR-α double knockout mice enhance injury during early stages of alcoholic liver disease [J]. Am J Physiol Gastrointest Liver Physiol, 2015, 308(5): G403-G415.
[45]	Shearn CT, Orlicky DJ, Petersen DR . Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease [J]. Exp Mol Pathol, 2018, 104(1): 1-8.
[46]	Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters [J]. Drug Metab Rev, 2017, 49(2): 1-15.
[47]	Chen F, Li DY, Zhang B, et al. Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance [J]. Drug Metab Rev, 2018, 50(3): 369-397.
[48]	Xie H, Sun S, Cheng X, et al. Dysregulations of Intestinal and Colonic UDP-glucuronosyltransferases in Rats with Type 2 Diabetes[J]. Drug Metab Pharmacokinet, 2013, 28(5): 427-434.
[49]	Dostalek M, Court MH, Hazarika S, et al. Diabetes Mellitus Reduces Activity of Human UDP-Glucuronosyltransferase 2B7 in Liver and Kidney Leading to Decreased Formation of Mycophenolic Acid Acyl-Glucuronide Metabolite [J]. Drug Metab Dispos, 2011, 39(3): 448-455.
[50]	Liu H, Wu B, Pan G, et al. Metabolism and Pharmacokinetics of Mangiferin in Conventional Rats, Pseudo-Germ-Free Rats, and Streptozotocin-Induced Diabetic Rats[J]. Drug Metab Dispos, 2012, 40(11): 2109-2118.
[51]	Koide CL, Collier AC, Berry MJ, et al. The effect of bamboo extract on hepatic biotransforming enzymes-Findings from an obese-diabetic mouse model [J]. J Ethnopharmacol, 2011, 133(1): 37-45.
[52]	Noce A, Fabrini R, Mariarita Dessì, et al. Erythrocyte glutathione transferase activity: a possible early biomarker for blood toxicity in uremic diabetic patients [J]. Acta Diabetologica, 2014, 51(2): 219-224.
[53]	蔡晶晶, 孟倩丽, 郭海科, 等. 血红素加氧酶-1在糖尿病视网膜病变患者外周血单个核细胞中的表达 [J]. 眼科新进展, 2014, 34(1): 37-40.
[54]	Li Z, Xu Y, Liu X, et al. Urinary Heme Oxygenase-1 as a potential biomarker for early diabetic nephropathy [J]. Nephrology, 2017, 22(1): 58-64.
[55]	Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells [J]. Trends Biochem Sci, 2016, 41(3): 211-218.
[56]	Gestl SA, Green MD, Shearer DA, et al. Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers [J]. Am J Pathol, 2002, 160(4): 1467-1479.
[57]	郑冰冰, 印泽远, 张晶波, 等. UGT2B7在子宫内膜癌组织中的表达及其临床意义 [J]. 徐州医学院学报, 2016, 36(5): 330-334.
[58]	Wijayakumara DD, Hu DG, Meech R, et al. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines [J]. J Pharmacol Exp Ther, 2015, 354(3): 417-425.
[59]	Margaillan G, Lévesque E, Guillemette C. Epigenetic Regulation of Steroid Inactivating UDP-Glucuronosyltransferases by microRNAs in Prostate Cancer [J]. J Steroid Biochem Mol Biol, 2015, 155(Pt A): 85-93.
[60]	Utsunomiya H, Ito K, Suzuki T,et al. Steroid sulphatase and estrogen sulphotransferase in human endometrial carcinoma [J]. Clin Cancer Res, 2004, 10(17): 5850-5856.
[61]	Smuc T, Rupreht R, Sinkovec J, et al. Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer [J]. Mol Cell Endocrinol, 2006, 248(1/2): 114-117.
[62]	Yin H, Fang J, Liao L, et al. Upregulation of heme oxygenase-1 in colorectal cancer patients with increased circulation carbon monoxide levels, potentially affects chemotherapeutic sensitivity [J]. BMC Cancer, 2014, 14: 436.
[63]	黄红艳, 李潇珊, 曹仕琼. 血红素加氧酶-1在大肠癌中的表达及临床意义 [J]. 临床消化病杂志, 2015, 27(5): 18-22.
[64]	Li Z, Zhang Y, Jin T, et al. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers [J]. BMC Cancer, 2015, 15(1): 207.
[65]	Li LS, Reddy S, Lin ZH, et al. NQO1-mediated tumor-selective lethality and radiosensitization for head and neck cancer [J]. Mol Cancer Ther, 2016, 15(7): 1757-1767.
[66]	Cui X, Li L, Yan G, et al. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma [J]. BMC Cancer, 2015, 15(1): 244.
[67]	Hauptstock V, Kuriakose S, Schmidt D, et al. Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide [J]. Biochem Biophys Res Commun, 2011, 412(4): 606-611.
[68]	Ramsey CP, Glass CA, Montgomery MB, et al. Expression of Nrf2 in Neurodegenerative Diseases[J]. J Neuropathol Exp Neurol, 2007, 66(1): 75-85.
[69]	Duan W, Zhang R, Guo Y, et al. Nrf2 activity is lost in the spinal cord and its astrocytes of aged mice [J]. In Vitro Cell Dev Biol Anim, 2009, 45(7): 388-397.
[70]	Yamazaki H, Tanji K, Wakabayashi K, et al. Role of the Keap1/Nrf2 pathway in neurodegenerative diseases [J]. Pathol Int, 2015, 65(5): 210-219.
[71]	Ahn SH, Monsanto SP, Miller C, et al. Pathophysiology and Immune Dysfunction in Endometriosis[J]. Biomed Res Int, 2015: 795976.
[72]	Lai ZZ, Yang HL, Ha SY, et al.Cyclooxygenase-2 in Endometriosis[J]. Int J Biol Sci, 2019, 15(13): 2783-2797.
[73]	Ray K, Fahrmann J, Mitchell B, et al. Oxidation-sensitive nociception involved in endometriosis-associated pain [J]. Pain, 2015, 156(3): 528-539.
[74]	Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis [J]. Semin Reprod Med, 2014, 18(7): 1016-1018.
[75]	Greaves E, Horne AW, Jerina H, et al. EP2 receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis [J]. Sci Rep, 2017, 7: 44169.
[76]	Lousse JC, Defrere S, Colette S, et al. Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis [J]. Hum Reprod, 2010, 25(3): 734-741.
[77]	Nandakishore R, Yalavarthi PR, Kiran YR, et al. Selective cyclooxygenase inhibitors: current status [J]. Curr Drug Discov Technol, 2014, 11(2): 127-132.
[78]	Cho S, Park SH, Choi YS, et al. Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis [J]. Gynecol Obstet Invest, 2010, 69(2): 93-100.
[79]	Rakhila H, Cédric Carli, Marlène Daris, et al. Identification of multiple and distinct defects in prostaglandin biosynthetic pathways in eutopic and ectopic endometrium of women with endometriosis [J]. Fertil Steril, 2013, 100(6): 1650-1659.
[80]	Da LC, Da BM, Donabela FC, et al. PTGS2 down-regulation in cumulus cells of infertile women with endometriosis [J]. Reprod Biomed Online, 2017, 35(4): 379-386.
[81]	Maia HJ, Maltez A, Studard E, et al. Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium [J]. Gynecol Endocrinol, 2005, 21(1): 57-61.
[82]	Maia HJ, Maltez A, Studard E, et al. Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium [J]. Gynecol Endocrinol, 2005, 21(1): 57-61.
[83]	Tanaka Y, Maher JM, Chen C, et al. Hepatic is- chemia-reperfusion induces renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice[J]. Mol Pharmacol, 2007, 71(3): 817-825.
[84]	陈洁, 敖英, 乐江. 心肌缺血再灌注损伤对大鼠肝细胞色素P450酶代谢的影响 [J]. 中国药理学与毒理学杂志, 2013, 27(3): 321-327.